Vector Vitale develops therapeutic solutions that correct the chirality of amino acids and restore protein conformation to address the underlying causes of degenerative diseases. Their platform targets conditions such as solid tumors, diabetes, and Parkinson’s disease by re-establishing cellular homeostasis and enhancing treatment efficacy without harmful side effects.
Funding
$780K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Degenerative diseases arise from malfunctions at the molecular level, specifically involving amino acid chirality and protein conformation, which current life sciences methods struggle to address at their source. This leads to damaged receptors, disrupted signaling pathways, and ultimately, a breakdown of cellular homeostasis. Current treatments often fail to address these underlying causes, resulting in limited efficacy and potential side effects.
Solution
Vector Vitale is developing therapeutic solutions that target the root causes of degenerative diseases by correcting the chirality of amino acids and restoring proper protein conformation. Their approach aims to re-establish cellular homeostasis and enhance treatment efficacy without harmful side effects. The technology is based on a model that views the human organism as a complex hierarchical system, addressing imbalances at the atomic and molecular levels to restore cellular function. By controlling amino acid chirality, correcting defective transcription factors and protein conformation, and restoring homeostasis, Vector Vitale aims to change the paradigm of treatment for degenerative diseases.
Target Audience
The primary target audience includes patients suffering from solid tumors, diabetes, obesity, and Parkinson’s disease, as well as individuals aged 25-60 seeking preventative care against degenerative disorders.
Features
- Therapeutic solutions focused on correcting amino acid chirality in proteins.
- Correction of defective transcription factors, ribosomes, and protein conformation.
- Restoration of homeostasis in live cells by addressing imbalances at the atomic and molecular levels.
- First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases (Phase 1).